Enzyme Enhancement Activity of N-octyl-beta-valienamine on Beta-glucosidase Mutants Associated with Gaucher Disease.
From: Department of Child Neurology, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.
Biochimica et biophysica acta
- Publish Date: May 2007
- ISSN: 0006-3002
- Volume: 1772
- Issue: 5
- Pages: 587-96
- Medium: Print
- Language: English
- Citation (JAMA): Lei Ke, Ninomiya Haruaki, Suzuki Michitaka, et al. Enzyme Enhancement Activity of N-octyl-beta-valienamine on Beta-glucosidase Mutants Associated with Gaucher Disease.. Biochim. Biophys. Acta May 2007;1772:587-96
Abstract
Gaucher disease (GD), caused by a defect of beta-glucosidase (beta-Glu), is the most common form of sphingolipidosis. We have previously shown that a carbohydrate mimic N-octyl-beta-valienamine (NOV), an inhibitor of beta-Glu, could increase the protein level and enzyme activity of F213I mutant beta-Glu in cultured GD fibroblasts, suggesting that NOV acted as a pharmacological chaperone to accelerate transport and maturation of this mutant enzyme. In the current study, NOV effects were evaluated in GD fibroblasts with various beta-Glu mutations and in COS cells transiently expressing recombinant mutant proteins. In addition to F213I, NOV was effective on N188S, G202R and N370S mutant forms of beta-Glu, whereas it was ineffective on G193W, D409H and L444P mutants. When expressed in COS cells, the mutant proteins as well as the wild-type protein were localized predominantly in the endoplasmic reticulum and were sensitive to Endo-H treatment. NOV did not alter this localization or Endo-H sensitivity, suggesting that it acted in the endoplasmic reticulum. Profiling of N-alkyl-beta-valienamines with various lengths of the acyl chain showed that N-dodecyl-beta-valienamine was as effective as NOV. These results suggest a potential therapeutic value of NOV and related compounds for GD with a broad range of beta-Glu mutations.
Mesh Headings (Keywords): Animals, Cells, Cultured, Cercopithecus aethiops, Endoplasmic Reticulum, Gaucher Disease, Glycoside Hydrolases, Hexosamines, Humans, Mutation, Recombinant Proteins, beta-Glucosidase
Check for Full Text / PubMed Unique Identifier (PMID): 17363227
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.